Literature DB >> 10830407

Cost-effectiveness analysis in Parkinson's disease: determining the value of interventions.

A D Siderowf1, R G Holloway, M B Stern.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 10830407     DOI： 10.1002/1531-8257(200005)15:3<439::AID-MDS1004>3.0.CO;2-F

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  8 in total

Review 1.  Cost effectiveness of pharmacotherapies in early Parkinson's disease.

Authors:  Karla M Eggert; Jens P Reese; Wolfgang H Oertel; Richard Dodel
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 2.  A review of the health-related quality of life and economic impact of Parkinson's disease.

Authors:  Clare H Dowding; Claire L Shenton; Sam S Salek
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

3.  Cost-effectiveness analysis of dopamine agonists in the treatment of Parkinson's disease in Japan.

Authors:  T Shimbo; K Hira; M Takemura; T Fukui
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

4.  Functional improvement after subthalamic stimulation in Parkinson's disease: a non-equivalent controlled study with 12-24 month follow up.

Authors:  M Capecci; R A Ricciuti; D Burini; V G Bombace; L Provinciali; M Iacoangeli; M Scerrati; M G Ceravolo
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-06       Impact factor: 10.154

Review 5.  Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease.

Authors:  G W Ross; H Petrovitch
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 6.  Economic Evaluation of Interventions in Parkinson's Disease: A Systematic Literature Review.

Authors:  Nafsika Afentou; Johan Jarl; Ulf-G Gerdtham; Sanjib Saha
Journal:  Mov Disord Clin Pract       Date:  2019-04-11

7.  Pharmacotherapy in the management of early Parkinson's disease: cost-effectiveness and patient acceptability.

Authors:  Esther Cubo
Journal:  Clinicoecon Outcomes Res       Date:  2010-09-06

8.  Evaluation of exercise-induced modulation of glial activation and dopaminergic damage in a rat model of Parkinson's disease using [11C]PBR28 and [18F]FDOPA PET.

Authors:  Caroline C Real; Janine Doorduin; Paula Kopschina Feltes; David Vállez García; Daniele de Paula Faria; Luiz R Britto; Erik Fj de Vries
Journal:  J Cereb Blood Flow Metab       Date:  2017-12-22       Impact factor: 6.200
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.